Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib Development

Vandana Singh
1 min read
0
In this article:

Verastem Oncology Inc (NASDAQ: VSTM) entered into a credit facility with Oxford Finance LLC for up to 0 million to primarily support the continued development, commercial preparation, and potential launches of VS-6766 and defactinib.

  • Verastem drew an initial $25 million term loan at closing. The Company can access up to an additional $125 million in a series of tranches, $75 million of which are based on certain pre-determined milestones and $50 million at the lender's discretion.

  • Related: Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why.

  • The Company had cash, cash equivalents, and an investment balance of $100.3 million. Considering the initial drawdown of $25.0 million at closing, the Company would have had a pro-forma cash balance of $125.3 million and an expected cash runway through 2025.

  • The Company posted a Q4 FY21 EPS loss of $(0.08), down from (0.09) a year ago.

  • Price Action: VSTM shares are up 8.82% at $1.30 during the market session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories